Global Pulmonary Arterial Hypertension Market Opportunities and Forecast 2020-2027

  • DLR2942
  • 11 January, 2022
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Pulmonary Arterial Hypertension Market, By Drug Type (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase5 (PDE-5), Vasodilators, Others ), By Application (Oral, Intravenous, Inhalation) and opportunities and forecast 2020-2027

Pulmonary Arterial Hypertension Market Overview

The strong product pipeline and novel drug combination awaiting approval are expected to spice up the market growth. moreover, pneumonic arterial hypertension could be a rare respiratory organ disorder that's commonly children in youngsters. The high proportion of kids suffering from untreated PAH offers vast market enlargement opportunities and is poised to market the utilization of pulmonary hypertension high blood pressure medication.

However, side effects related to the drugs could negatively influence the market progression. Vasodilators are widely prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. Studies report that vasodilators have variety of facet effects like tachycardia, edema, heart palpitations, chest pain, etc. because of the substantial side effects associated with the utilization of vasodilators in chronically sick patients, the U.S. fda regulates the utilization of this drug. Further, the PAH medication that treat high pressure level and dilate blood vessels need to submit cheap assurance concerning the protection and effectiveness of the medication. These medication need the U.S. government agency approval before commercializing within the market. The fda drug approval represents an advanced method that demonstrates the protection and efficaciousness of the drug. Hence, a long regulatory method and facet effects associated with the utilization of PAH medication would possibly hamper the business growth throughout the forecast timeframe.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Type, Application, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Sumitomo dainippon pharma,Sellas, ISA Pharmaceuticals, Generex Biotechnology,Immatics, Shionogi & Co., Ltd., BrightPath Biotherapeutics, AMAL Therapeutics (AMAL).


The covid-19 Impact on Pulmonary Arterial Hypertension Market:

Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
 
Pulmonary Arterial Hypertension market Segment Overview



By Drug Type, The endothelin receptor antagonist segment is predicted to witness largest market share ,the rising demand for endothelin receptor antagonist drugs. These medicine are widely suggested as a targeted therapy to reverse the damage of the heart & lungs, slow the progression of PAH, and dilate blood vessels among others. The clinical studies have confirmed that patient with pulmonary arterial quantity produces high amount of endothelin that always ends up in high blood pressure. Thus, associate degree endothelin receptor antagonist is very prescribed by physicians to cut back the number of endothelin gift within the blood vessels. Moreover, progressive investments for analysis and development of endothelin receptor antagonist can promote the section growth. Recently there has been a speedy growth in analysis targeting endothelin receptor that has alternative therapeutic blessings, principally within the treatment of pulmonary arterial hypertension.
 
By Application,The oral segment within the pulmonary arterial hypertension market dominated  market share, the oral route of administration that gives a broad vary of indefinite quantity forms like tablets, capsules, and solutions among others. The oral route is that the most most well-liked route for drug administration attributed to its edges as well as the convenience of drug administration, patient compliance, and non-invasiveness. Oral therapies increase patient safety and luxury at a reasonable value. what is more, speedy delivery of medicine, the next rate of bioavailability, and high efficaciousness among others can propel the section revenue.
 
Market Analysis, Insights and Forecast – By Drug Type
·       Prostacyclin And Prostacyclin Analogs
·       Soluble Guanylate Cyclase (SGC) Stimulators
·       Endothelin Receptor Antagonist (ERA)
·       Phosphodiesterase 5 (PDE-5)
·       Vasodilators
·       Others

Market Analysis, Insights and Forecast – By Application
·       Oral
·       Intravenous
·       Inhalation

Pulmonary Arterial Hypertension Market Regional Overview

Region-wise, in terms of regions ,U.S. dominated the North America pulmonary arterial hypertension market and driven by the numerous factors like the availability of a high variety of board-certified physicians, growing hospital admissions related to PAH, and growing supportive government initiatives among others. The prevalence of PAH is increasing within the country attributed to the chance factors comprising smoking, HIV, inactive mode, and alcohol consumption among others. additionally, in the U.S., the Orphan Drug Act (ODA) was introduced in 1983 to supply incentives for business investment in treatments for PAH.

In Europe, germany market accounted of the rise within the prevalence of pneumonic arterial high blood pressure, optimum health personnel, and helpful government initiatives to enhance the health of patients tormented by PAH within the country.

Pulmonary Arterial Hypertension Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Pulmonary Arterial Hypertension Market Competitor overview

Some key developments and strategies adopted by manufacturers in thePulmonary Arterial Hypertension are highlighted below.

·      In 2019, Bristol-Myers Squibb Company, an american pharmaceutical company got the approval to acquire Celgene corporation ,The transaction is anticipated to make a number one specialty company which might address the requirements of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, an organization that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters within the USA.

Pulmonary Arterial Hypertension Market, Key Players -

·       Johnson & Johnson Services, Inc.
·       United Therapeutics Corporation
·       Pfizer, Inc.
·       Acceleron Pharma, Inc.
·       Gilead Sciences, Inc.
·       Bayer AG
·       GlaxoSmithKline Plc. (GSK)

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the pulmonary Arterial Hypertension Market during the forecast period?

A. Pulmonary Arterial Hypertension market is expected to record a CAGR of ~ XX % during the forecast period.

Q2. Which segment is projected to hold the largest share in the pulmonary Arterial Hypertension Market?

A. Endothelin Receptor Antagonist (ERA)segment is projected to hold the largest share in the Pulmonary Arterial Hypertension Market

Q3. What are the driving factors for the pulmonary Arterial Hypertension Market?

A. An improvement within the pool of cancer patients, technological enhancements, new drug development within the field of cancer, increase in government support, growth of geriatric population, and lasting impact of peptide cancer vaccine, the growing variety of pipeline studies , these are main factors driving the growth of automotive lighting market.

Q4. Which Segments are covered in the pulmonary Arterial Hypertension Market report?

A. Drug Type , Application and Region, these segments are covered in the pulmonary Arterial Hypertension Market report.

Q5. Which are the prominent players offering Pulmonary Arterial Hypertension Market?

A. Johnson & Johnson Services, Inc., United Therapeutics Corporation, Pfizer, Inc., Acceleron Pharma, Inc., Gilead Sciences, Inc., Bayer AG, GlaxoSmithKline Plc. (GSK).
Pulmonary Arterial Hypertension Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Pulmonary Arterial Hypertension Market analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – ByDrug Type
        • 5.2.1. Prostacyclin And Prostacyclin Analogs
        • 5.2.2. Soluble Guanylate Cyclase (SGC) Stimulators
        • 5.2.3. Endothelin Receptor Antagonist (ERA)
        • 5.2.4. Phosphodiesterase 5 (PDE-5)
        • 5.2.5. Vasodilators
        • 5.2.6. Others
      • 5.3. Market Analysis, Insights and Forecast – By Application
        • 5.3.1. Oral
        • 5.3.2. Intravenous
        • 5.3.3. Inhalation
      • 5.4. Market Analysis, Insights and Forecast – By Region
        • 5.4.1. North America
        • 5.4.2. Europe
        • 5.4.3. Asia Pacific
        • 5.4.4. Latin America, Middle East, and Africa

      6. North America Pulmonary Arterial Hypertension Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – ByDrug Type
        • 6.2.1. Prostacyclin And Prostacyclin Analogs
        • 6.2.2. Soluble Guanylate Cyclase (SGC) Stimulators
        • 6.2.3. Endothelin Receptor Antagonist (ERA)
        • 6.2.4. Phosphodiesterase 5 (PDE-5)
        • 6.2.5. Vasodilators
        • 6.2.6. Others
      • 6.3. Market Analysis, Insights and Forecast – By Application
        • 6.3.1. Oral
        • 6.3.2. Intravenous
        • 6.3.3. Inhalation
      • 6.4. Market Analysis, Insights and Forecast – By Country
        • 6.4.1. UK
        • 6.4.2. Germany
        • 6.4.3. France
        • 6.4.4. Italy
        • 6.4.5. Spain
        • 6.4.6. Russia
        • 6.4.7. Rest of Europe

      7. Asia Pacific Pulmonary Arterial Hypertension Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – ByDrug Type
        • 7.2.1. Prostacyclin And Prostacyclin Analogs
        • 7.2.2. Soluble Guanylate Cyclase (SGC) Stimulators
        • 7.2.3. Endothelin Receptor Antagonist (ERA)
        • 7.2.4. Phosphodiesterase 5 (PDE-5)
        • 7.2.5. Vasodilators
        • 7.2.6. Others
      • 7.3. Market Analysis, Insights and Forecast – By Application
        • 7.3.1. Oral
        • 7.3.2. Intravenous
        • 7.3.3. Inhalation
      • 7.4. Market Analysis, Insights and Forecast – By Country
        • 7.4.1. China
        • 7.4.2. India
        • 7.4.3. Japan
        • 7.4.4. Australia
        • 7.4.5. South East Asia
        • 7.4.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Pulmonary Arterial Hypertension Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – ByDrug Type
        • 8.2.1. Prostacyclin And Prostacyclin Analogs
        • 8.2.2. Soluble Guanylate Cyclase (SGC) Stimulators
        • 8.2.3. Endothelin Receptor Antagonist (ERA)
        • 8.2.4. Phosphodiesterase 5 (PDE-5)
        • 8.2.5. Vasodilators
        • 8.2.6. Others
      • 8.3. Market Analysis, Insights and Forecast – By Application
        • 8.3.1. Oral
        • 8.3.2. Intravenous
        • 8.3.3. Inhalation
      • 8.4. Market Analysis, Insights and Forecast – By Country
        • 8.4.1. Brazil
        • 8.4.2. Saudi Arabia
        • 8.4.3. UAE
        • 8.4.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Johnson & Johnson Services, Inc.
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. United Therapeutics Corporation
      • 9.6. Pfizer, Inc.
      • 9.7. Acceleron Pharma, Inc.
      • 9.8. Gilead Sciences, Inc.
      • 9.9. Bayer AG

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934